SI1735349T1 - Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov - Google Patents

Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov

Info

Publication number
SI1735349T1
SI1735349T1 SI200531162T SI200531162T SI1735349T1 SI 1735349 T1 SI1735349 T1 SI 1735349T1 SI 200531162 T SI200531162 T SI 200531162T SI 200531162 T SI200531162 T SI 200531162T SI 1735349 T1 SI1735349 T1 SI 1735349T1
Authority
SI
Slovenia
Prior art keywords
assessing
risk
cardiovascular disease
ischemic cardiovascular
phosphorylcholine conjugates
Prior art date
Application number
SI200531162T
Other languages
English (en)
Inventor
Faire Ulf De
Johan Frostegard
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of SI1735349T1 publication Critical patent/SI1735349T1/sl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
SI200531162T 2004-04-15 2005-04-15 Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov SI1735349T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52138404P 2004-04-15 2004-04-15
PCT/GB2005/001463 WO2005100405A2 (en) 2004-04-15 2005-04-15 Phosphorylcholine conjugates and corresponding antibodies

Publications (1)

Publication Number Publication Date
SI1735349T1 true SI1735349T1 (sl) 2010-12-31

Family

ID=34981497

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200531048T SI1797893T1 (sl) 2004-04-15 2005-04-15 Protitelesa proti fosforilholinskim konjugatom
SI200531162T SI1735349T1 (sl) 2004-04-15 2005-04-15 Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200531048T SI1797893T1 (sl) 2004-04-15 2005-04-15 Protitelesa proti fosforilholinskim konjugatom

Country Status (15)

Country Link
US (4) US8012483B2 (sl)
EP (3) EP1735349B1 (sl)
JP (2) JP4891228B2 (sl)
CN (4) CN1968965B (sl)
AT (2) ATE463254T1 (sl)
AU (2) AU2005233361B2 (sl)
CA (2) CA2776927C (sl)
CY (2) CY1110188T1 (sl)
DE (2) DE602005023428D1 (sl)
DK (2) DK1797893T3 (sl)
ES (2) ES2362222T3 (sl)
PL (2) PL1797893T3 (sl)
PT (2) PT1735349E (sl)
SI (2) SI1797893T1 (sl)
WO (1) WO2005100405A2 (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525462A (ja) 2004-12-22 2008-07-17 エイボン プロダクツ インコーポレーテッド しわの外観を減少させるための方法および組成物
JP2008530019A (ja) * 2005-02-07 2008-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 死細胞または瀕死細胞に露出する抗原に対する結合タンパク質を用いて自己免疫の症状および炎症性の症状を低減するための方法
US7745146B2 (en) * 2006-07-26 2010-06-29 Inova Diagnostics, Inc. Compositions and methods for diagnosing patients with acute atherosclerotic syndrome
CA2669863A1 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Cardiovascular autoimmune disease panel and methods of using same
MX2010004885A (es) * 2007-10-30 2010-08-04 Athera Biotechnologies Ab Diagnostico y metodos terapeuticos y composiciones para enfermedades cardiovasculares.
JP2011527016A (ja) * 2008-07-07 2011-10-20 アセラ・バイオテクノロジーズ・アーベー アルツハイマー病についての新規の治療および診断方法
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
AU2011223222B2 (en) * 2010-03-04 2016-11-17 Athera Biotechnologies Ab Antibodies against phosphorylcholine in combination therapy with biologic agents
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
US9310380B2 (en) 2010-11-17 2016-04-12 National University Corporation Ehime University Method for analyzing proteins contributing to autoimmune diseases, and method for testing for said diseases
ES2732838T3 (es) 2011-08-09 2019-11-26 Athera Biotechnologies Ab Nuevos anticuerpos frente a fosforilcolina
CN103906532B (zh) * 2011-08-09 2018-01-26 阿瑟拉生物技术公司 结合磷酰胆碱（pc）和/或pc结合物的抗体
US10046021B2 (en) 2013-02-05 2018-08-14 Tpcera Ltd. Phosphorylcholine conjugates and uses thereof
CN105102485B (zh) 2013-02-05 2019-04-19 特普塞拉公司 磷酸胆碱缀合物及其用途
US11065319B2 (en) * 2014-02-04 2021-07-20 3Dt Holdings, Llc Methods for diagnosing and reducing incidences of cardiac allograft rejection
US10500260B2 (en) * 2014-02-04 2019-12-10 3Dt Holdings, Llc Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
EP3208275B1 (en) 2014-10-15 2019-01-09 NOF Corporation Phosphorylcholine group-containing compound and phosphorylcholine complex
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
WO2018220224A1 (en) * 2017-06-02 2018-12-06 Medirista Biotechnologies Ab Lipid-related antigens and antibodies directed against them
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
WO2024028192A1 (de) 2022-08-04 2024-02-08 Pentracor Gmbh Verwendung von phosphocholin-humanserumalbumin-konjugaten zur blockade von c-reaktivem protein

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402664A1 (fr) 1977-09-07 1979-04-06 Agronomique Inst Nat Rech Produits de couplage phosphorylcholine, composes amines procede d'obtention et applications
JPS6251699A (ja) * 1985-08-30 1987-03-06 Nichirei:Kk 単クロ−ン性抗体およびそれを用いる測定法
US5955584A (en) 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
EP0257778B1 (en) 1986-08-06 1995-03-22 Scripps Clinic And Research Foundation Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas
JPH02188532A (ja) 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン
AU5522390A (en) 1989-04-19 1990-11-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Process for removing c-reactive protein and anti-phosphorylcholine antibodies from biological fluids
JP3283041B2 (ja) * 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
CA2098101A1 (en) 1990-12-10 1992-06-10 Carl R. Alving A vaccine against cholesterol to prevent hypercholesterolemia and atherosclerosis
JPH07504817A (ja) * 1992-03-03 1995-06-01 ザ ロックフェラー ユニヴァーシティ Ｂ２９（Ｉｇ‐βまたはＩｇ−γ）を含むレセプタ複合体およびその利用
WO1994014454A1 (en) * 1992-12-29 1994-07-07 Entremed, Inc. Vaccines against sterols
DE69411154T2 (de) 1993-02-22 1998-10-22 Alza Corp Mittel zur oralen gabe von wirkstoffen
US5455032A (en) 1993-07-29 1995-10-03 The United States Of America As Represented By The Department Of Health And Human Services Use of phosphocholine hapten conjugates in vaccines
US6375925B1 (en) 1996-11-08 2002-04-23 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
WO1998021581A1 (en) 1996-11-08 1998-05-22 The Regents Of The University Of California Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US6300308B1 (en) * 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
EP1095271B1 (en) 1998-07-03 2003-09-17 Athera Biotechnologies Ab Method of diagnosing cardiovascular disease and early atherosclerosis
DE60045869D1 (de) 1999-10-26 2011-06-01 Univ California Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
SE0000855D0 (sv) 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
WO2001088547A2 (en) 2000-05-12 2001-11-22 The Regents Of The University Of California Standardized oxidized ldl assay
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
DE10041515A1 (de) * 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
WO2004091520A2 (en) * 2003-04-11 2004-10-28 The Regents Of The University Of California Methods and compositions for treating atherosclerosis

Also Published As

Publication number Publication date
ES2357606T3 (es) 2011-04-28
EP2258728A1 (en) 2010-12-08
CN105699669A (zh) 2016-06-22
AU2005233361B2 (en) 2011-02-24
US20160131661A1 (en) 2016-05-12
US10222382B2 (en) 2019-03-05
ATE480778T1 (de) 2010-09-15
PL1797893T3 (pl) 2010-09-30
CA2562550A1 (en) 2005-10-27
CN103743898B (zh) 2019-02-05
US8012483B2 (en) 2011-09-06
AU2005233361A1 (en) 2005-10-27
CA2562550C (en) 2013-09-24
PL1735349T3 (pl) 2011-03-31
EP1797893A3 (en) 2007-06-27
PT1797893E (pt) 2010-07-14
CA2776927C (en) 2014-08-12
CN103743898A (zh) 2014-04-23
WO2005100405A2 (en) 2005-10-27
CY1111659T1 (el) 2015-10-07
JP2008501636A (ja) 2008-01-24
JP2011099871A (ja) 2011-05-19
ES2362222T3 (es) 2011-06-29
EP1797893A2 (en) 2007-06-20
ATE463254T1 (de) 2010-04-15
US20140186360A1 (en) 2014-07-03
DK1735349T3 (da) 2010-12-06
DK1797893T3 (da) 2010-08-02
JP5366987B2 (ja) 2013-12-11
CN103908669A (zh) 2014-07-09
EP1735349A2 (en) 2006-12-27
JP4891228B2 (ja) 2012-03-07
CN1968965B (zh) 2015-12-16
CY1110188T1 (el) 2015-01-14
WO2005100405A3 (en) 2006-04-13
SI1797893T1 (sl) 2010-08-31
CA2776927A1 (en) 2005-10-27
US20120039895A1 (en) 2012-02-16
DE602005023428D1 (de) 2010-10-21
CN1968965A (zh) 2007-05-23
US20070286868A1 (en) 2007-12-13
EP1797893B1 (en) 2010-04-07
EP1735349B1 (en) 2010-09-08
DE602005020474D1 (de) 2010-05-20
AU2011202334B2 (en) 2012-12-06
PT1735349E (pt) 2010-12-14
AU2011202334A1 (en) 2011-06-09
CN103908669B (zh) 2017-07-04

Similar Documents

Publication Publication Date Title
SI1735349T1 (sl) Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov
NO20054451D0 (no) Fremgangsmate og innretning for friksjonssveising
NL1026089A1 (nl) Scintillator welke een geïntegreerde collimator heeft en werkwijze voor het vervaardigen daarvan.
DE602006019404D1 (de) Docetaxel-immuntest
ITMI20061751A1 (it) Albero cavo e procedimento per la realizzazione
ATE399802T1 (de) Amidfunktionelle polymere, zusammensetzungen und verfahren
WO2006138048A3 (en) Formulations comprising fluphenazine or derivatives thereof
WO2006098998A3 (en) Methods and compositions for modulating vascular integrity
MX2007009591A (es) Metodos para disposicion mejorada de farmacos.
NL1024195A1 (nl) Inspectiewerkwijze voor een belichtingsinrichting en een belichtingsinrichting.
FI20045295A0 (fi) Embossauslaite ja menetelmä embossauslaitteen säätämiseksi
BRPI0402499B1 (pt) armação lateral e método para reparar ou manter uma armação lateral para um conjunto roda-truque de vagão ferroviário que suporta um vagão ferroviário.
WO2006074443A3 (en) Pde5 inhibitor compositions and methods for immunotherapy
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
ITTO20030365A1 (it) Dispositivo e procedimento per determinare la posizione
ITMI20042356A1 (it) Composizione farmaceutica orodisperdibile e procedimento per prepararla
FR2893833B1 (fr) Appareil d'orthopedie dento-faciale.
ATE377608T1 (de) Hemoglobin konjugate
PL1649947T3 (pl) Urządzenie do mechanicznego łączenia części lub czegoś podobnego
ITMO20050086A1 (it) 'dispositivo antifumo per sigarette o simili.'
ES1054552U (es) Dispositivo para la fijacion de elementos tubulares
ITCR20040011A1 (it) Struttura metallica per pedane, rampe e simili, adatta a compensare o superare dislivelli
ITUD20040001A1 (it) Procedimento per la rilevazione in linea
NL1031169A1 (nl) Werkwijze voor de vervaardiging van een railbovendeel alsmede railbovendeel.
ITFI20050159A1 (it) Metodo di imaging ecografico per la caratterizzazione delle proprieta' non lineari di un mezzo e dispositivo impiegante detto metodo